-
Je něco špatně v tomto záznamu ?
Iron chelators as mitophagy agents: Potential and limitations
T. Brogyanyi, Z. Kejík, K. Veselá, P. Dytrych, D. Hoskovec, M. Masařik, P. Babula, R. Kaplánek, T. Přibyl, J. Zelenka, T. Ruml, M. Vokurka, P. Martásek, M. Jakubek
Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie.
2024 ;
179 (-) :
117407.
[pub] 20240911
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, přehledy
Perzistentní odkaz
https://www.medvik.cz/link/bmc24018735
- MeSH
- chelátory železa * farmakologie terapeutické užití MeSH
- homeostáza účinky léků MeSH
- lidé MeSH
- mitochondrie * metabolismus účinky léků MeSH
- mitofagie * účinky léků MeSH
- železo * metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018735
- 003
- CZ-PrNML
- 005
- 20241024111229.0
- 007
- ta
- 008
- 241015e20240911fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2024.117407 $2 doi
- 035 __
- $a (PubMed)39265234
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Brogyanyi, Tereza $u BIOCEV, First Faculty of Medicine, Charles University, Vestec 252 50, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, U Nemocnice 5, 1, Prague 28 53, Czech Republic
- 245 10
- $a Iron chelators as mitophagy agents: Potential and limitations / $c T. Brogyanyi, Z. Kejík, K. Veselá, P. Dytrych, D. Hoskovec, M. Masařik, P. Babula, R. Kaplánek, T. Přibyl, J. Zelenka, T. Ruml, M. Vokurka, P. Martásek, M. Jakubek
- 520 9_
- $a Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
- 650 12
- $a mitofagie $x účinky léků $7 D063306
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chelátory železa $x farmakologie $x terapeutické užití $7 D007502
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a mitochondrie $x metabolismus $x účinky léků $7 D008928
- 650 12
- $a železo $x metabolismus $7 D007501
- 650 _2
- $a homeostáza $x účinky léků $7 D006706
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kejík, Zdeněk $u BIOCEV, First Faculty of Medicine, Charles University, Vestec 252 50, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic
- 700 1_
- $a Veselá, Kateřina $u BIOCEV, First Faculty of Medicine, Charles University, Vestec 252 50, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic
- 700 1_
- $a Dytrych, Petr $u 1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, Prague 121 08, Czech Republic
- 700 1_
- $a Hoskovec, David $u 1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, Prague 121 08, Czech Republic
- 700 1_
- $a Masařik, Michal $u BIOCEV, First Faculty of Medicine, Charles University, Vestec 252 50, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Brno CZ-625 00, Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Brno 625 00, Czech Republic
- 700 1_
- $a Babula, Petr $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, Brno CZ-625 00, Czech Republic
- 700 1_
- $a Kaplánek, Robert $u BIOCEV, First Faculty of Medicine, Charles University, Vestec 252 50, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic
- 700 1_
- $a Přibyl, Tomáš $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Prague 166 28, Czech Republic
- 700 1_
- $a Zelenka, Jaroslav $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Prague 166 28, Czech Republic
- 700 1_
- $a Ruml, Tomáš $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Prague 166 28, Czech Republic
- 700 1_
- $a Vokurka, Martin $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, U Nemocnice 5, 1, Prague 28 53, Czech Republic
- 700 1_
- $a Martásek, Pavel $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic
- 700 1_
- $a Jakubek, Milan $u BIOCEV, First Faculty of Medicine, Charles University, Vestec 252 50, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague 120 00, Czech Republic. Electronic address: Milan.Jakubek@lf1.cuni.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 179 (20240911), s. 117407
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39265234 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111223 $b ABA008
- 999 __
- $a ok $b bmc $g 2201543 $s 1230708
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 179 $c - $d 117407 $e 20240911 $i 1950-6007 $m Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20241015
